Moderna, Inc. (MRNA) on Decifer

Why it ranks here

It is not profitable yet.
Revenue is expected to grow about 20% a year, profits grew 22% over the past year, and growth is speeding up, not slowing down.
It keeps a high share of every sale as profit.
It is riding an active market tailwind and has the balance sheet to fund its growth.
It is not watering down its owners with new shares.
Our durability check found pressure on this name, which costs it a few points.

The current read

The evidence on MRNA lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

Healthcare, Biotech & Devices: Moderna sits in the biotech layer of the Healthcare, Biotech & Devices story.
GLP-1 & Metabolic Health: Moderna pioneered mRNA vaccine technology that underpinned the COVID-19 vaccine franchise. Beyond respiratory vaccines, Moderna has an oncology pipeline (mRNA-4157 personalised cancer vaccine in Phase 3 with Merck) and rare disease programmes. The mRNA platform provides a manufacturing infrastructure advantage for any indication requiring a new vaccine or therapeutic.

Read the full MRNA research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.